Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 Nov;23(6):910-917.
doi: 10.1111/hae.13317. Epub 2017 Aug 6.

Prophylaxis use among males with haemophilia B in the United States

M Ullman  1 , Q C Zhang  2 , S D Grosse  3 , M Recht  4 , J M Soucie  5 ; Hemophilia Treatment Center Network Investigators
Affiliations
Multicenter Study

Prophylaxis use among males with haemophilia B in the United States

M Ullman et al. Haemophilia. 2017 Nov.

Abstract

Introduction: Prophylaxis is considered the optimal treatment for persons with moderate to severe haemophilia (factor activity between 1-5% of normal and <1% of normal respectively) in countries where safe factor concentrates are available and economically feasible. Historically, prophylactic treatment has not been well studied in the haemophilia B (HB) population due to difficulties in obtaining a sufficiently large sample.

Aim: This study examines the prevalence of prophylaxis use among a robust sample of persons with HB in the United States and its association with specific demographic and clinical characteristics.

Methods: Using data collected between 1998 and 2011 for the Centers for Disease Control and Prevention's Universal Data Collection project, we analysed data on 2428 males with moderate to severe HB aged 2-79 years who were seen at 135 federally funded haemophilia treatment centres.

Results: Prevalence of prophylactic treatment in our sample was 35% among children and youth (ages 2-19) and 14% among adults (age 20 and older). Increased HB prophylaxis use was significantly associated with younger age (<40 years), Hispanic ethnicity, severe disease and self-infusion, while decreased use was associated with above-normal body mass index (BMI) in adults. Health care coverage was vital, although type of coverage did not appear to influence access.

Conclusions: Our analysis confirms previous reports of lower prevalence of prophylaxis use among individuals with HB compared to those with haemophilia A and adds to the body of knowledge regarding treatment patterns among a historically understudied population.

Keywords: BMI; ethnicity; haemophilia B; obesity; overweight; prophylaxis.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Predicted probability of prophylaxis use in males with moderate to severe haemophilia B by race/ethnicity
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. National Hemophilia Foundation. [Accessed April 3, 2017];MASAC recommendations concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding) Document #179. http://www.hemophilia.org.
    1. World Federation of Hemophilia. [Accessed April 3, 2017];Guidelines for the management of hemophilia. http://www.wfh.org.
    1. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe hemophilia A and B. J Int Med. 1992;232:25–32. - PubMed
    1. Aledort LM, Haschmeyer RH, Petterson H the Orthopaedic Outcome Study Group. A longtudinal study of orthopedic outcomes for severe factor-VIII-deficient haemophiliacs. J Int Med. 1994;236:391–399. - PubMed
    1. Tagliferri A, Feola G, Molinari AC, Santoro C, Rivolta GF, Cultrea DB, et al. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study. Thromb and Haemost. 2015;114:35–45. - PubMed

Publication types